Results 21 to 30 of about 2,931,663 (352)
Diagnostics, 2023 Determination of salivary flow rate and oral status in patients with primary Sjögren’s Syndrome (pSS) and diffuse cutaneous systemic sclerosis (dcSSc) and comparison with control subjects.
Ana Glavina +6 more
doaj +1 more source
Is Th17-Targeted Therapy Effective in Systemic Lupus Erythematosus?
Current Issues in Molecular Biology, 2023 Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with a broad spectrum of clinical manifestations. The proposed pathophysiological hypotheses of SLE are numerous, involving both innate and adaptive abnormal immune responses.
Marin Petrić, Mislav Radić
doaj +1 more source
Treatment of a patient with severe systemic sclerosis (SSc) using CD19-targeted CAR T cells
Annals of the Rheumatic Diseases, 2023 Several lines of evidence suggest a role of B cells in severe systemic sclerosis (SSc) pathophysiology: elevated levels of B- cell stimulating factors, disturbed B- cell homeostasis with expansion of naïve and decrease of memory B cells, 1 and anti ...
C. Bergmann +20 more
semanticscholar +1 more source
State-of-the-art evidence in the treatment of systemic sclerosis
Nature Reviews Rheumatology, 2023 Systemic sclerosis (SSc) is a rare autoimmune connective tissue disease with multi-organ involvement, fibrosis and vasculopathy. Treatment in SSc, including early diffuse cutaneous SSc (dcSSc) and the use of organ-specific therapies, has improved, as ...
J. Pope +5 more
semanticscholar +1 more source
Exercise and physical therapy for systemic sclerosis [PDF]
, 2022 Objectives: This is a protocol for a Cochrane Review (intervention). The objectives are as follows:.
Espinosa-Cuervo, Gisela +4 more
core +1 more source
Annals of the Rheumatic Diseases, 2023 Objective To develop evidence-based recommendations for the non-pharmacological management of systemic lupus erythematosus (SLE) and systemic sclerosis (SSc).
I. Parodis +24 more
semanticscholar +1 more source
Systemic Sclerosis-Specific Antibodies: Novel and Classical Biomarkers
Clinical reviews in allergy and immunology, 2022 Disease-specific autoantibodies are considered the most important biomarkers for systemic sclerosis (SSc), due to their ability to stratify patients with different severity and prognosis. Anti-nuclear antibodies (ANA), occurring in subjects with isolated
I. Cavazzana +8 more
semanticscholar +1 more source
Pathophysiology of systemic sclerosis (scleroderma)
Kaohsiung Journal of Medical Sciences, 2022 Systemic sclerosis (scleroderma) is an autoimmune‐triggered chronic fibrosing disease that affects the skin and many other organs. Its pathophysiology is complex and involves an early endothelial damage, an inflammatory infiltrate and a resulting ...
A. Rosendahl, K. Schönborn, T. Krieg
semanticscholar +1 more source
The Lancet, 2023 Systemic sclerosis, also known as scleroderma, is a rare and complex autoimmune connective-tissue disease. Once considered an untreatable and unpredictable condition, research advancements have improved our understanding of its disease pathogenesis and clinical phenotypes and expanded our treatment armamentarium.
Volkmann, Elizabeth R +2 more
openaire +4 more sources
Myofibroblast transcriptome indicates SFRP2hi fibroblast progenitors in systemic sclerosis skin
Nature Communications, 2021 Skin and lung fibrosis in systemic sclerosis (SSc) is driven by myofibroblasts, alpha-smooth muscle actin expressing cells. The number of myofibroblasts in SSc skin correlates with the modified Rodnan skin score, the most widely used clinical measure of ...
T. Tabib +11 more
semanticscholar +1 more source